en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Data › Receptor Action And Clearance — Questions and Answers

Receptor Action And Clearance — Questions and Answers

By Editorial Desk · published 2026-05-13 · last reviewed 2026-06-02 · Data

This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-06-02. Anything still debated is marked as such rather than presented as settled.

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Analytical Measurement And Stability

Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.

Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.

Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorPresent on pituitary somatotroph cells
Signal pathwayGs, cyclic AMP, protein kinase ASequence follows receptor activation
Main measured effectGrowth hormone releaseInsulin-like growth factor 1 shifts indirectly
Half-life, binding formSeveral daysExtended through serum albumin association
Half-life, unmodified formAbout 30 minutesLimited mainly by enzymatic cleavage

CJC-1295 Structure And Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Related pages on this site

Background and Molecular Features

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

Background from the literature

== Commercials == "Dominator" – an energy drink using Pudzianowski's profile is being distributed in Poland. Mariusz appeared in a Met-rx commercial which aired during the U.S. broadcast of the 2007 World's Strongest Man contest.

== Source text == The source of the contents will be mentioned as follows on Wikipedia articles included under the scope of this project: This article incorporates text from a free content work. Licensed under CC BY 4.0. Text taken from Anatomy and Physiology​, J. Gordon Betts et al, Openstax. https://openstax.org/books/anatomy-and-physiology/pages/4-1-types-of-tissues.

=== Commercial development === By the late 1960s, increasing volumes of whey had become an economic and environmental problem for the New Zealand dairy industry, creating an incentive to develop higher-value uses for its whey protein. In September 1969, Dr. Alex Malaspina, vice-president responsible for new product development and quality control at The Coca-Cola Export Corporation, approached the New Zealand Dairy Board in search of a reliable supply of soluble whey protein for acidic, carbonated beverages, with potential demand estimated at as much as 10,000 tons annually. At the time, the New Zealand industry did not know how to manufacture such a product because its existing heat-precipitated whey protein was insoluble and unsuitable for beverages. The Dairy Board and the New Zealand Dairy Research Institute (NZDRI) investigated several separation technologies, and Malaspina, Dr. R. Fenton-May from Coca-Cola, and NZDRI engineer Dave Woodhams examined ultrafiltration, reverse osmosis, and other processes in the United States. Woodhams recommended ultrafiltration, and in September 1970 NZDRI produced a whey protein concentrate containing 65% protein and meeting Coca-Cola's requirements for beverage solubility and clarity. Malaspina subsequently worked with Brazilian food scientist Roberto H. Moretti on a process for producing whey protein suitable for acidic beverages. Their U.S.

Sources: en.wikipedia.org

Further detail

==== Indications ==== Dronabinol, also known as tetrahydrocannabinol (THC), is a natural compound extracted from plants. It is available as Marinol® and Syndros®. It is used as an appetite stimulant in anorexia-associated weight loss in HIV/AIDS patients. An increase in patients' appetite and daily calorie intake with minimal improvement in weight and nausea is reported. Dronabinol is also indicated for chemotherapy-induced nausea and vomiting in cancer patients failing to respond to conventional antiemetics. Dronabinol is also used for cancer-related chronic pain in Europe.

David Russell, consumer advocate, chief executive of Consumer NZ (1990–2007) (born 1942). 30 September – Nigel Latta, clinical psychologist and television host (Beyond the Darklands, The Politically Incorrect Parenting Show, Nigel Latta Blows Stuff Up) (born 1967).

They were, collectively, a very representative group: two engineers, two chemists, two biologists, one representative of agricultural science, one geologist, one representative of veterinary science, one representative of manufacturing industries, and one representative of the agricultural and pastoral industries. Robertson attended the Council's first official meeting, in Melbourne, on 22 June 1926, as the acting chairman of the South Australian Committee.

Sources: en.wikipedia.org

Background from the literature

Pharmacology is often studied by focusing on specific systems, such as endogenous neurotransmitter systems. The major systems studied in pharmacology can be categorized by their ligands and their receptors which include, but are not limited to, acetylcholine (ACh), adenosine, adrenaline, anandamide, aspartate, glutamate, glycine, purines, substance P, eicosanoids, GABA, dopamine (DA), histamine, serotonin (5-HT), serine, cannabinoids, opioids, melatonin, vasopressin (ADH), and norepinephrine (NE). Molecular targets in pharmacology include receptors, enzymes, and membrane transport proteins. Enzymes can be targeted with enzyme inhibitors. Receptors are typically categorized based on structure and function. Major receptor types studied in pharmacology include G protein coupled receptors, ligand gated ion channels, and receptor tyrosine kinases. Network pharmacology is a subfield of pharmacology that combines principles from pharmacology, systems biology, and network analysis to study the complex interactions between drugs and targets (receptors or enzymes etc.) in biological systems. The topology of a biochemical reaction network determines the shape of drug dose-response curve as well as the type of drug-drug interactions, thus can help designing efficient and safe therapeutic strategies. The topology Network pharmacology utilizes computational tools and network analysis algorithms to identify drug targets, predict drug-drug interactions, elucidate signaling pathways, and explore the polypharmacology of drugs.

=== Local helium spray === This method is a small variation from the one above. It still requires the part to be tested to be connected to a helium leak detector and all steps above and vacuum pump sizing based on the part size are followed. However, the outer surface of the part to be tested is sprayed with a localized stream of helium tracer gas where the spray head will be moved across the part. Thus, correlation between maximum leakage signal and helium spray head location will allow the operator to pinpoint the leaky area for possible repair or further investigation.

== Reduction of food packaging == Reduced packaging and sustainable packaging are becoming more frequent, although excessive overpackaging is still common. The motivations can be government regulations, consumer pressure, retailer pressure, and cost control. Reduced packaging often saves packaging costs. In the UK, a Local Government Association survey produced by the British Market Research Bureau compared a range of outlets to buy 29 common food items, and found that small, local retailers and market traders "produced less packaging and more that could be recycled than the larger supermarkets."

Kefir ( kə-FEER; alternative spellings: kephir or kefier) is a fermented milk drink similar to a thin yogurt or ayran that is made from kefir grains, a specific type of mesophilic symbiotic culture. It is prepared by inoculating the milk of cows, goats, or sheep with kefir grains. Kefir is a common breakfast, lunch or dinner drink consumed in countries of West Asia and Central and Eastern Europe. Kefir is consumed at any time of the day, alongside European pastries like zelnik (zeljanica), burek and banitsa/gibanica, and is an ingredient in cold soups.

Sources: en.wikipedia.org

Frequently asked questions

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

How does the albumin-binding group alter behavior?

It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.

What do studies generally measure?

Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.

How are the two variants distinguished in a laboratory?

The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.

Network